Botaneco receives up to $3.6 million Agri-Opportunities funding from Agriculture and Agri-Food Canada

    CALGARY, May 13 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), specializing
in the manufacture of high-value proteins and oils in plant seeds, announced
today that its subsidiary, Botaneco Specialty Ingredients Inc., has been
notified that a repayable contribution of up to $3,630,000 was approved by
Agriculture and Agri-Food Canada under their Agri-Opportunities program. The
Agri-Opportunities program will fund up to one-third of the eligible
expenditures made by Botaneco over a two-year project which began in the first
quarter of 2009.
    "This non-dilutive funding from the Agri-Opportunities program will
support the continued expansion of Botaneco's manufacturing capabilities in
Calgary. Increasing capacity and optimizing production efficiencies will allow
Botaneco to meet the growing demand for its innovative all-natural ingredients
for personal care products," said James Szarko, Chief Executive Officer of
SemBioSys. "As part of this project, Botaneco will investigate new sources of
safflower seed in Canada and develop new products that offer benefits to
formulators and manufacturers in the personal care industry."
    The funding bears no interest and Botaneco anticipates repayment to begin
in 2013, through equal installments over a five year period. The funds will
also support the expansion of Botaneco product sales into new international

    About SemBioSys

    Calgary, Alberta-based SemBioSys is a world leader in manufacturing
high-value proteins and oils in plant seeds. With its unique, proprietary
platform, SemBioSys provides partners with product enablement, exceptionally
low cost and unprecedented scalability. The Company applies this platform with
high selectivity to opportunities where it has a unique competitive advantage.
Since its inception, SemBioSys has produced more than 50 non-native proteins
and oils using its patented seed technology, demonstrating applicability
across a broad range of industries such as pharmaceuticals, personal care and
industrial products. The Company's current pharmaceutical development programs
include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo
AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the
Toronto Stock Exchange under the ticker SBS. More information is available at

    About Botaneco

    Botaneco, a subsidiary of SemBioSys, is the global developer and marketer
of innovative oleosome-based ingredients to the personal care and OTC topical
markets. As a technologically driven provider of high performance, proprietary
oleosome-based ingredients, Botaneco is committed to developing innovative
ingredients that offer multifunctional, tangible and documented benefits to
both formulators and consumers. Botaneco's head office and manufacturing
facility is located in Calgary, Canada and its satellite office in Bensalem,
PA. More information is available and can be accessed at

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.

For further information:

For further information: SemBioSys Genetics Inc., Abby Garfunkel,
Investor Relations, Phone: (403) 717-4185, E-mail:;
The Trout Group, Christine Labaree, Managing Director, Phone: (617) 583-1307,
E-mail:; The Equicom Group Inc., Ross Marshall, Vice
President, Phone: (416) 815-0700 ext. 238, E-mail:

Organization Profile

SemBioSys Genetics Inc.

More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890